ING Group’s XBiotech XBIT Stock Holding History

ING Group’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-53,611	Closed	-$1.12M	–	606
2016 Q2	$1.12M	Buy	+53,611	New	+$774K	0.02%	245

Other funds holding XBIT

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ING Group's XBIT Position: Q3 2016 in Review

ING Group sold out of XBiotech (XBIT) in Q3 2016, closing a stake of 53,611 shares — an estimated $1.12M sold.

ING Group first reported a position in XBIT in Q2 2016 and held it in 1 quarter. The position peaked at $1.12M in Q2 2016. 48 funds tracked by Wall St. Rank hold XBIT as of Q3 2016.

ING Group reported no remaining XBiotech position as of Q3 2016 after selling out during the quarter.
ING Group sold 53,611 XBiotech shares in Q3 2016, an estimated $1.12M.
ING Group first reported a position in XBiotech in Q2 2016 and held it in 1 quarter.
ING Group's XBiotech position peaked at $1.12M in Q2 2016.
48 funds tracked by Wall St. Rank held XBiotech as of Q3 2016.

Based on ING Group's 13F filing for Q3 2016, filed 14 Nov 2016.